Pyk2 promotes tumor progression in multiple myeloma
نویسندگان
چکیده
منابع مشابه
Pyk2 promotes tumor progression in multiple myeloma.
Proline-rich tyrosine kinase 2 (Pyk2) is a member of the focal adhesion kinase family that has been recently linked to tumor development. However, its role in modulating multiple myeloma (MM) biology and disease progression remains unexplored. We first demonstrated that patients with MM present with higher expression of Pyk2 compared with healthy individuals. By using loss-of-function approache...
متن کاملAlteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
Many cancers, including multiple myeloma (MM), retain more cytosolic iron to promote tumor cell growth and drug resistance. Higher cytosolic iron promotes oxidative damage due to its interaction with reactive oxygen species generated by mitochondria. The variation of mitochondrial biogenesis in different stages of MM disease was evaluated using gene expression profiles in a large clinical datas...
متن کاملBone Marrow Microenvironment in Multiple Myeloma Progression
Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the bone marrow (BM) microenvironment. Indeed, the BM niche appears to play an important role in differentiation, migration, proliferation, survival, and drug resistance of the malignant plasma cells. The BM niche is composed of a cellular compartment (stromal cells, osteoblasts, osteo...
متن کاملMultiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملTreatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2014
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2014-03-563981